Phase I (Completed)
-
Identifying an appropriate set of DNA samples for polymorphism analysis
-
Resequencing 200 candidate genes
-
Establishing a polymorphism database
-
Developing technology for identifying genetic variants in human genes
-
Considering the ethical, legal, and social implications of EGP research
|
Phase II
-
Multidisciplinary functional studies of human genetic variants
-
Population-based studies of exposure and allele–disease associations
-
Developing technology for Phase II studies including toxicogenomics
-
Refining the EGP SNP database
-
Considering the ethical, legal, and social implications of EGP research
-
Resequencing additional EGP candidate genes
|
Phase III
-
Population-based studies of exposure and allele–disease associations based on Phase I and II
-
Developing animal models for disease susceptibility; dose–response studies
-
Risk assessment studies related to population-based dose–response relationships
-
Developing technology for Phase III studies
-
Targeted screening of high-risk populations
-
Refining the EGP SNP database
-
Considering the ethical, legal, and social implications of EGP research
-
Resequencing additional EGP candidate genes (i.e., those involved in metabolism, signal transduction, and apoptosis
|
